-
Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious
Thursday, July 17, 2025 - 11:37am | 469Read More...Shares of Johnson & Johnson (NYSE:JNJ) are under pressure Thursday, despite a strong second-quarter earnings report. Here are some key analyst takeaways. BofA Securities analyst Tim Anderson reiterated a Neutral rating, while raising the price target from $161 to $175. Guggenheim Securities...
-
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
Thursday, April 17, 2025 - 4:43pm | 702Read More...Eli Lilly & Co. (NYSE:LLY) shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market projected to more than triple in size by 2030. The stock surged, closing the day up 14....
-
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025
Wednesday, December 25, 2024 - 10:00am | 2500Read More...The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks witnessed a stellar rally this year, analysts still expect some blue-chip equities to rise further as they forecast a better return potential. Dow’s Performance In 2024 The...
-
4 Reasons To Buy, 2 Controversies Surrounding AstraZeneca
Friday, September 22, 2017 - 9:51am | 501Read More...Bernstein upgraded shares of AstraZeneca plc (ADR) (NYSE: AZN), giving four reasons for its optimistic assessment. All the same, the firm also harped on two controversies surrounding the company. As such, Bernstein upgraded shares of AstraZeneca from Market Perform to Outperform and lifted its...
-
Which Pharma Players Dominate The Lung Cancer Space?
Wednesday, January 25, 2017 - 3:40pm | 946Read More...Lung and bronchus cancer is the leading cause of cancer deaths in the United States, according to the National Cancer Institute. Lung cancer is of two types, namely non-small cell lung cancer, or NSCLC and small cell lung cancer, or SCLC, with the former more prevalent than the latter. Estimates by...
-
Dow 20K - It's All In Your Mind
Wednesday, December 21, 2016 - 3:50pm | 476Read More...Despite the approach of Christmas Day, the beginning of Hanukkah and the start of a new year, some investors are finding joy and excitement elsewhere: the Dow Jones Industrial Average. However, there are those who aren't in the same spirit, wondering what exactly is the true meaning of Dow 20...
-
What If Trump Keeps Badmouthing Drug Pricing?
Wednesday, December 7, 2016 - 2:38pm | 400Read More...Pharmaceutical companies breathed a sigh of relief when Donald Trump prevailed on Election Day. His opponent, Hillary Clinton, had made prescription drug pricing a centerpiece of her campaign. However, according to Bernstein analyst Tim Anderson, pharma stocks may not be off the hook when Trump...
-
Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict
Tuesday, August 9, 2016 - 11:49am | 385Read More...Tim Anderson, MD, a senior analyst at Bernstein, took a deep dive into Bristol-Myers Squibb Co (NYSE: BMY)'s announcement last Friday that its Checkmate-026 trial exploring the cancer fighting drug Opdivo in 1L lung failed. Related Link: Bristol-Myers Hit With A Trio Of Analyst Price Target...
-
No More Paper
Sunday, May 29, 2016 - 5:04pm | 724Read More...Certain things for certain places leave an impression on you. For me, there is one thing from my time spent on the trading floor at the Chicago Mercantile Exchange from 1985–1992, that will never escape my mind: the paper. In other words, the tremendous of amount of excess paper that covered...
-
Goldman: High Yield Selloff Won't Stabilize Until Oil Does
Monday, December 14, 2015 - 10:37am | 505Read More...Friday's trading session saw a large spike in high-yield ETF volumes, resulting in single-day record volume. Tim Anderson of TJM Investments said Friday's trading activity was also an exercise in "sell what you can, if not what you want to." Lotfi Karoui of Goldman Sachs noted that 2015 could be...
-
Floor Trader: Why Goldman Is Wrong (Again) On $20 Oil Prediction
Monday, September 14, 2015 - 7:58am | 508Read More...Tim Anderson was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick. Crude oil prices are down substantially over the past 52 weeks. The United States Oil Fund LP (NYSE: USO) is down 57 percent, while the VelocityShares 3X Long Crude...
-
Why Netflix And Google Are No House Of Cards
Sunday, July 19, 2015 - 1:48pm | 385Read More...In a report published Friday, MND Partners' Tim Anderson noted that Netflix, Inc. (NASDAQ: NFLX) and Google Inc (NASDAQ: GOOG)(NASDAQ: GOOGL) are leading the upside in the NASDAQ and that these stocks are no "House of Cards." Netflix's shares rallied 18 percent on...
-
Anderson On Apple: Watch Volume Closely, It Was 70% Higher Than Average On Thursday
Friday, July 10, 2015 - 8:39am | 478Read More...Apple Inc. (NASDAQ: AAPL) shares fell more than 2 percent on Thursday amid chatter from Goldman Sachs' trading desk. The bank noted four reasons the tech giant could be trading down -- China, poor Watch demand, smaller buyback and hedge fund/mutual fund activity. On Friday morning, with...
-
Expert Roundtable: Is The Fed Just 'Kicking The Can Down The Road'?
Thursday, June 18, 2015 - 10:20am | 714Read More...The Federal Open Market Commission released its updated economic projections for the next two years on Wednesday, slashing GDP forecasts for 2015, while showing a mildly hawkish medium-to-long-term outlook on the economy. Meanwhile, the Federal Reserve announced that it would keep interest...
-
Everything You Need To Know Before Today's Fed Announcement
Wednesday, June 17, 2015 - 1:11pm | 544Read More...At 2 p.m. this afternoon, the Federal Open Market Committee will release its economic projections for the upcoming two years. More importantly, the central bank will announce whether or not it will move to raise interest rates this month and likely hint at the timing of future increases. Short-...














